Shareholders meeting

3rd July, 2026 BSE Limited National Stock Exchange of India Limited P. J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400 051 BSE Scrip Code: 543635 NSE Symbol: PPLPHARMA Sub: Notice of the 6th Annual General Meeting (‘AGM’) and Annual Report for the financial year 2025–26 Dear Sir / Madam, Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) and further to our intimation dated 19th June, 2026, please find enclosed herewith the Annual Report of the Company for the FY 2025-26 including the Business Responsibility & Sustainability Report along with the Notice of the AGM, scheduled to be held on Thursday, 30th July, 2026 at 3:00 p.m. (IST) through Video Conferencing / Other Audio Visual Means. The Notice of the AGM along with the Annual Report for FY 2025-26, is being sent through electronic mode to those Members whose email addresses are registered with the Company/Depository Participant(s) (‘DPs’)/MUFG Intime India Private Limited, Registrar to an Issue & Share Transfer Agent. Further, in accordance with Regulation 36(1)(b) of the SEBI Listing Regulations, a physical communication containing the weblink and Quick Response (QR) code for accessing the Notice of the AGM and Annual Report for FY 2025-26 is being sent to those Members whose email addresses are not registered. The said Annual Report along with the Notice of the AGM is also available on the website of the Company under the ‘Annual Report’ tab at https://www.piramalpharma.com/financial- reports. Kindly take the above on record. Thank you. Yours sincerely, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Encl.: a/a Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, Maharashtra, 400070 T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com www.piramalpharma.com Scaling Innovation. Elevating Science. Piramal Pharma Limited Annual Report 2025-26 Scaling Innovation What’s Elevating Science Inside Scaling Innovation, Elevating Science is more than a theme—it is our commitment to shaping a healthier world. In today’s time, prioritising health and wellness is essential, and we power science to develop innovative the Report drugs and products that drive better outcomes for patients and consumers everywhere. Our dedication to uncompromising quality standards, investment in niche products and capabilities, strong execution, and speed to 02-17 18-25 26-41 market ensures that life-changing therapies reach those in need faster and more reliably. Corporate Performance Advancing Sustainability With facilities across the globe offering integrated services, Overview Overview at Piramal we are equipped to tackle complex supply chain challenges, building resilience and ensuring equitable access to care. At the same time, we embrace sustainable operations, protecting 02 About Piramal Pharma 20 FY2026 Performance Highlights 28 Environment 06 Our Presence 22 Leadership Message 30 Our People and Culture the planet while advancing human health. Because true 08 Our Business 38 Governance progress means caring not only for people, but also for the world we share. 14 Board of Directors Together, through scaling innovation and elevating science, we are creating a future where health is prioritized, breakthroughs 42-81 82-168 169-334 are accelerated, and wellness is universal. Management Discussion Statutory Financial and Analysis Reports Statements 44 Macroeconomic Overview 82 Report on Corporate Governance 169 Standalone 45 Global Pharmaceutical 101 Board’s Report 251 Consolidated Industry Overview 123 Business Responsibility and 48 Business-wise Performance Sustainability Report 68 Financial Review 70 Quality 74 Technology and Digital Transformation 78 Enterprise Risk Management 335-355 Notice 335 AGM Notice To know more about us, explore piramalpharma.com Annual Report 2025-26 Corporate Performance Advancing Management Discussion Statutory Financial Piramal Pharma Limited Overview Overview Sustainability at Piramal and Analysis Reports Statements About Piramal Pharma Advancing the Care Continuum with Innovation and Science Piramal Pharma Limited (PPL) is an innovation-focused global pharmaceutical, health and wellness company. Supported by a diverse workforce of over 7,000 people, we deliver a portfolio of differentiated products and services spanning CDMO, complex hospital generics and consumer health Our Purpose and wellness. Our operations are underpinned by an integrated We stay true to our purpose of worldwide network of 171 'Doing Well and manufacturing and development facilities, strategically located across key geographies and complemented by a well- established distribution Doing Good' footprint across more than 100 countries. We are steadfast in our commitment to improving patient and consumer well-being through the consistent delivery of quality, reliable and innovative solutions. While serving the needs of our patients by following three basic tenets and customers remains central to our purpose, we also strive to create long-term value for our Making a positive difference to the health employees, partners, communities, shareholders of our patients and consumers through and the environment. This commitment is anchored our products and services in our core values and is reflected in our decisions, behaviours and conduct, guiding both individual Serving our patients, customers, actions and organisational practices. consumers, community, employees, partners, stakeholders and our planet Living our values in our everyday actions, decisions and conduct at a personal and corporate level 1. Includes one facility through our minority investment in Yapan Bio 02 03 Annual Report 2025-26 Corporate Performance Advancing Management Discussion Statutory Financial Piramal Pharma Limited Overview Overview Sustainability at Piramal and Analysis Reports Statements Backed by Vision, Legacy and Progress Piramal Pharma Highlights FY2026 Piramal Pharma is a part of the Piramal Group, a global business Economic c Imon pg al co tm Ge ura idte db u bi ylt o hn st eh e rc io nr ce v lea slu ae ns o tf K en po hw il le od sog pe, c ot fi o ‘Dn, C ina gr e a en ld l Perfo rmance Expertise and Doing Good’, the Group has built a strong presence across financial 8,869 Crore 890 Crore s pe or sv itic ive es l, p ih ma prm aca tic ne gu lt ii vc ea sls Wan id r e oa pl e rast ta iote n— ss ph aa np nin ing i n od veu rs t 3r 0ie s ow uh ni tle ri es act K n Revenue from Operations Capital Expenditure meco r ac i da ril p mer re ass sn c r mre mpth itea tn s ee ca lvr uk vt 2s e0, gt nh roae tr hno u elip t ti heis Resilience Imp w l a tio 5,631 Crore 17 Core Values business practices and sustainable value creation. Gross Contribution1 No. of Facilities2 The cornerstone of our business Piramal Group Since 1980 40+ Years 23,000+ grit Care Humilit I 1 IT, D1 A35 Crore 1 Co0 u0 nt+ ries with Commercial Presence of Stewardship Employees Global Commercial Entrepreneurship Truste Environment Presence in Offices in 100+ 30+ SBTi Target 42% Markets Countries Approved Decarbonisation Reduction in GHG Plan Emissions3 by FY2030 22.6% 1,91,887 KL Reduction in GHG Emissions3 Water Recycled Compared to FY2022 Baseline 29,413 KL 6,520 Rainwater Harvested Saplings Planted Social and Governance 7,285 30% Total No. of Employees4 Women Representation on the Board 38 Zero Fatalities Successful Regulatory in Last 5 Years Inspections CSR Projects Zero Cases with Piramal Foundation of Human Rights Violation 1. Gross contribution= Revenue from operations - Cost of goods sold (material cost) 2. Includes one facility through our minority investment in Yapan Bio 3. Scope 1 and 2 GHG emission 4. Permanent employees 04 05 [Showing first 8,000 characters — download PDF for full document]